MOGAD, or myelin oligodendrocyte glycoprotein antibody-associated disease, is an autoimmune condition in which the immune system produces antibodies against a protein called MOG on the surface of myelin, the insulating sheath around nerve fibers in the brain, spinal cord, and optic nerves. It was only recently recognized as a disease distinct from both multiple sclerosis and neuromyelitis optica spectrum disorder, and it has its own diagnostic criteria, its own relapse behavior, and its own treatment considerations that set it apart from those better-known conditions.
How MOGAD Typically Presents
The most common way MOGAD announces itself is through optic neuritis, an inflammation of the optic nerve that causes sudden vision loss, eye pain with movement, and often disc swelling visible on exam. Bilateral involvement, where both eyes are affected simultaneously or in quick succession, is a hallmark that helps distinguish it from optic neuritis caused by MS. On MRI, the inflamed optic nerve tends to be swollen and show a long segment of signal abnormality toward the front of the nerve, sometimes with inflammation extending into the tissue surrounding the nerve sheath. The optic chiasm and the pathways behind it are usually spared.1PubMed Central. MOG antibody-associated optic neuritis 2PubMed. MOGAD: How It Differs From and Resembles Other Neuroinflammatory Disorders
Transverse myelitis, an inflammation of the spinal cord that causes weakness, numbness, or bladder problems, is the second most common presentation, seen in roughly a quarter of patients.3PubMed Central. Transverse myelitis in myelin oligodendrocyte glycoprotein antibody-associated disease Diagnosing MOGAD-related myelitis can be tricky: MRI is initially normal in up to one in ten patients, and abnormalities can resolve completely if imaging is delayed, leaving no visible footprint of the attack.
In children, the picture often looks different. The most frequent initial presentation in pediatric patients is acute disseminated encephalomyelitis (ADEM), a widespread brain inflammation that causes confusion, drowsiness, and sometimes seizures, along with large, poorly defined white-matter lesions on MRI. One study of 45 patients found that ADEM accounted for about a third of childhood presentations, while optic neuritis dominated in adults, appearing in over half.4PubMed. Clinical course, imaging, and pathological features of 45 adult and pediatric cases of myelin oligodendrocyte glycoprotein antibody-associated disease When researchers applied formal ADEM definitions to cerebral attacks in a larger cohort of 89 MOGAD patients, about 79% of children but only 36% of adults met those criteria, underscoring the age-related shift in how the disease behaves.5PubMed Central. Application of the ADEM Definition to Cerebral Attacks of MOG Antibody-Associated Disease
Who Gets MOGAD and How It Differs Across Age Groups
MOGAD can appear at any age, from toddlers to older adults, and it affects both sexes, though there is a slight female predominance. Clinical features shift meaningfully with age. Children are more likely to present with ADEM and brain involvement, while adults are more likely to experience isolated optic neuritis or myelitis. Perhaps the most clinically important age-related difference involves outcomes: adults face a higher risk of relapse and tend to have worse functional recovery compared to children.6PubMed. Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
That said, at least one single-center study found that male sex and pediatric-onset disease were associated with an increased risk of relapse, while adults whose first attack was unilateral optic neuritis were more likely to have a monophasic (one-and-done) course.7PubMed. Clinical characteristics of pediatric and adult myelin oligodendrocyte antibody-associated disease (MOGAD): A single-center study in the Northeast These findings are not always consistent across cohorts, which is part of what makes predicting relapse so difficult in individual patients.
Monophasic or Relapsing: The Central Uncertainty
One of the defining features of MOGAD, and one of its biggest clinical headaches, is that roughly half of patients never have another attack, while the other half relapse. In a large cohort of 326 patients followed for an average of about four years, 46% experienced at least one relapse.8PubMed Central. Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease A smaller study of 24 patients followed for a mean of 15 months found about 29% relapsed, while roughly 71% remained monophasic.9PubMed. Clinical risk factors for recurrence of myelin oligodendrocyte glycoprotein antibody-associated disease These differences in reported relapse rates partly reflect follow-up duration: the longer you watch, the more relapses accumulate.
The inability to confidently distinguish monophasic from relapsing patients at the time of a first attack creates a real dilemma. Committing someone to long-term immunosuppression after a single episode feels aggressive if they might never relapse. But waiting and watching means the next attack could cause permanent damage to vision or spinal cord function. Clinicians are essentially forced to weigh the risks of overtreatment against the risks of undertreatment in a state of genuine uncertainty.
What Predicts Whether Someone Will Relapse
Several factors have been linked to relapse risk, though none are reliable enough to use as a crystal ball. Persistently positive MOG antibody titers have been proposed as a biomarker, and there is logic to it: the monthly relapse risk drops from roughly 4% to about 0.5% after a patient becomes antibody-negative.10Journal of Neurology, Neurosurgery & Psychiatry. Predictors of relapse in MOG antibody associated disease: a cohort study But the relationship is not clean. In pediatric cohorts followed for nearly five years, about half of children became seronegative, a third stayed persistently positive, and some fluctuated, without any of these patterns reliably predicting who would and would not relapse.11PubMed Central. Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
How you treat the first attack seems to matter. Steroid treatment lasting more than one month was associated with monophasic disease, with an odds ratio of 0.2, meaning patients who received a longer steroid course had about one-fifth the odds of relapsing compared to those with shorter tapers.10Journal of Neurology, Neurosurgery & Psychiatry. Predictors of relapse in MOG antibody associated disease: a cohort study One study found that relapses were more common when patients were tapered to prednisone doses below 10 mg daily, and that patients who relapsed had a median steroid taper of just one and a half months compared to five months in those who stayed relapse-free. Most relapses in that study occurred within two months of stopping steroids entirely.11PubMed Central. Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Presentation type offers some clues too. Transverse myelitis at the first attack and male sex were both associated with a lower relapse risk in one cohort.10Journal of Neurology, Neurosurgery & Psychiatry. Predictors of relapse in MOG antibody associated disease: a cohort study Lifestyle factors are getting attention as well: a multicenter study found that older age at onset and a history of smoking were associated with greater disability risk, and smoking showed an association with relapse risk, though that link weakened after statistical adjustment. Body mass index had a nonlinear relationship with both relapse and disability, meaning the effect was not a simple more-is-worse pattern.12PubMed Central. Clinical and Modifiable Factors Associated With Disability and Relapse in MOGAD: A Multicentre Cohort Study
Treating Attacks and Preventing Relapses
Acute MOGAD attacks are almost always treated with high-dose intravenous corticosteroids, followed by a gradual oral taper. The evidence increasingly suggests that these tapers need to be slow, generally three months or longer, to reduce the risk of early relapse.13Journal of Neuro-Ophthalmology. The Treatment of Myelin Oligodendrocyte Glycoprotein Antibody Disease: A State-of-the-Art Review In children, escalating treatment beyond steroids alone during the first attack, with plasma exchange or intravenous immunoglobulin, was associated with a substantially lower relapse risk. At one year, only 4% of children who received escalation therapy relapsed, compared to 28% of those treated with steroids alone.14PubMed Central. Acute Attack Treatment Escalation and Subsequent Relapse Risk in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
For patients who have established relapsing disease, several maintenance therapies are used, though none have been validated through large randomized controlled trials specific to MOGAD. A meta-analysis pooling data from dozens of studies estimated the proportion of patients remaining relapse-free on each therapy:
- IVIG: about 79% relapse-free
- Mycophenolate (MMF): about 73% relapse-free
- Rituximab: about 66% relapse-free
- Azathioprine: about 65% relapse-free
All four significantly reduced annualized relapse rates compared to pretreatment levels, with IVIG and azathioprine showing the largest absolute reductions.15PubMed. Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease Tocilizumab, an interleukin-6 receptor blocker, showed the highest relapse-free rate (around 93%) in a small number of studies, though the wide confidence interval reflected limited data at the time.
More recently, a multicenter study across the Americas directly compared interleukin-6 receptor blockade to IVIG and found a lower hazard of relapse with the IL-6 blocker. The comparison was dose-dependent for IVIG: patients receiving lower doses of IVIG had a considerably higher relapse risk, while those on higher doses performed closer to the IL-6 blocker group.16PubMed Central. Interleukin-6 Receptor Blockade for Relapse-Prevention in MOGAD A Multicenter Observational Study Across the Americas This is an important nuance: how much IVIG someone receives, not just whether they receive it, appears to influence how well it works.
Getting the Diagnosis Right
MOGAD requires a combination of the right clinical picture, the right antibody test, and supportive MRI findings. The presence of MOG-IgG in serum, detected using a cell-based assay, is the core laboratory criterion.17PubMed. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria But testing is not straightforward. Not all assays perform equally, and patients with low-positive titers can be especially hard to classify. In one clinical-laboratory assessment, a standard cell-based assay without titration failed to confirm MOGAD in about 29% of patients, most of whom had optic neuritis or myelitis. Adding titration to the assay allowed diagnosis in additional cases.18PubMed. MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: a clinical-laboratory assessment
A critical distinction for patients and clinicians is that MOGAD is not a subtype of MS or NMOSD. Each condition targets a different cell type: NMOSD attacks astrocytes through aquaporin-4 antibodies, while MOGAD targets the oligodendrocytes that produce myelin.19PubMed Central. Updates in NMOSD and MOGAD Diagnosis and Treatment: A Tale of Two Central Nervous System Autoimmune Inflammatory Disorders This distinction matters for treatment: some MS therapies, like interferon-beta and natalizumab, may be ineffective or even harmful in MOGAD. Getting the right diagnosis early shapes everything that follows.
What Spinal Fluid Reveals
Cerebrospinal fluid (CSF) analysis in MOGAD tells a very different story from MS. Oligoclonal bands, the signature finding in MS, are absent in about 85-90% of MOGAD patients.20PubMed Central. Characteristics of cerebrospinal fluid oligoclonal band in anti-myelin oligodendrocyte glycoprotein (MOG) antibody associated disease In a detailed study of 163 lumbar punctures from 100 adults, the MRZ reaction, considered the most specific laboratory marker for MS, was negative in every single sample tested. When intrathecal antibody production was present at all, it was low, transient, and mostly restricted to acute attacks.21PubMed Central. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients
What the CSF does often show is inflammation: white blood cell counts were elevated in more than half of samples, with a median of 31 cells per microliter, and neutrophils turned up in over 40% of cases. Elevated neutrophils in CSF are unusual in MS and can be a useful distinguishing clue. Nearly half of samples showed signs of a leaky blood-brain barrier.21PubMed Central. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients Taken together, the spinal fluid profile in MOGAD looks more like acute inflammation than the chronic intrathecal immune activation seen in MS.
What Happens at the Tissue Level
The way MOGAD damages nerve tissue is distinct from both MS and NMOSD. In active lesions, the immune infiltrate includes granulocytes, macrophages, activated microglia, and complement deposits, all of which contribute to stripping myelin from nerve fibers during an acute attack. MOG antibodies appear to drive this damage through several routes: tagging the MOG protein so immune cells attack it, activating complement (part of the innate immune system that punches holes in cell membranes), and triggering antibody-dependent cell-mediated destruction.22PubMed Central. Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease
Pathology studies show complement deposited in all active white matter lesions, but interestingly, there is no preferential loss of the MOG protein itself. This argues against a model where the antibody simply causes MOG to be swallowed up by cells. Instead, MOG may function as an amplification factor: it does not necessarily start the demyelination, but once the immune system is activated, the anti-MOG antibodies ramp up the destruction through complement-mediated and cell-mediated pathways.23PubMed Central. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody The underlying reason tolerance breaks down in the first place, allowing the body to make antibodies against its own myelin, involves dysregulation of the immune checkpoints that normally delete or suppress self-reactive immune cells.24PubMed Central. Induction of immune tolerance in NMOSD and MOGAD
Fatigue, Pain, and the Invisible Burden
Between attacks, many MOGAD patients are not fine. Persistent fatigue, mood disturbances, chronic pain, and residual visual impairment are common complaints that standard disability scales tend to miss. Patient-reported outcome measures have highlighted these issues: fatigue and low mood are frequent even during clinical remission, and their impact on daily life is significant.25PubMed. Neuropsychologic impact of MOGAD: A patient reported outcomes study Pain and depression are highly prevalent in adults with MOGAD and strongly affect quality of life and the ability to carry out everyday activities.26PubMed. Pain, depression, and quality of life in adults with MOG-antibody-associated disease
This is an area where MOGAD care still has a lot of room to grow. Much of the clinical attention is focused, understandably, on preventing and treating relapses. But for patients living with the disease, the day-to-day burden of fatigue and pain between attacks can feel just as disabling as the attacks themselves. Routine screening for mood and pain symptoms is starting to gain traction in MOGAD clinics, though it is far from universal.
Vaccination and Other Triggers
Like many autoimmune conditions, MOGAD attacks sometimes follow infections or vaccinations, presumably because immune activation in one context can occasionally spill over into an autoimmune response. In children, ADEM presentations frequently follow a febrile illness.27Revista Brasileira de Neurologia. MOG Antibody Disease (MOGAD) Presenting as Acute Disseminated Encephalomyelitis (ADEM): Insights from Cerebrospinal Fluid Cytokine Profiling During the COVID-19 vaccination campaigns, a study identified 25 patients who developed acute inflammatory CNS disease after vaccination. Nearly half tested positive for MOG antibodies, and most of these antibody-positive cases occurred after the adenoviral-vector vaccine. A visible spike in new MOGAD cases in spring 2021 was attributed to post-vaccine onset.28PubMed Central. Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination
This does not mean vaccination causes MOGAD in any straightforward sense. Post-vaccine autoimmune events are rare, and the benefits of vaccination against COVID-19 were clear during the pandemic. But for clinicians managing someone with known MOGAD, these observations inform conversations about timing of vaccinations relative to immunosuppressive therapy and monitoring for new symptoms afterward.
Pregnancy and MOGAD
For women with MOGAD who are pregnant or planning a pregnancy, the limited available data is reassuring. In a retrospective study of 22 pregnancies, no relapses occurred during any of them. The annualized relapse rate dropped to zero during pregnancy, down from about 0.26 in the 12 months before conception, and remained low (about 0.09) in the 12 months postpartum.29PubMed. Relapse risk before, during and after pregnancy in MOG antibody-associated disorder: a two-center retrospective study An earlier study reached a similar conclusion, reporting a marked reduction in relapse rate during pregnancy and the postpartum period.30PubMed. Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated disease
The postpartum picture deserves some nuance. In the two-center study, the only postpartum relapses occurred in a single patient who had a steroid-dependent relapsing course before pregnancy. About half the women were on disease-modifying therapy during the postpartum period, which likely helped keep relapse rates low. For women with a low pre-pregnancy relapse rate, the postpartum period does not seem to carry the elevated risk that has been observed in some other autoimmune neurological conditions. These are small numbers, and prospective studies are needed, but what exists so far should be part of family-planning discussions for women with MOGAD.